Pilot study of bortezomib for patients with imatinib-refractory chronic myeloid leukemia in chronic or accelerated phase

Clinical Lymphoma, Myeloma and Leukemia

Volumn 11, Issue 4, 2011, Pages 355-360

  Santos, Fabio P S ^a   Kantarjian, Hagop ^a   McConkey, David ^a   O'Brien, Susan ^a   Faderl, Stefan ^a   Borthakur, Gautam ^a   Ferrajoli, Alessandra ^a   Wright, John ^b   Cortes, Jorge ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Bortezomib; Chronic myelogenous leukemia; Proteasome inhibitors

Indexed keywords

BORTEZOMIB; HEMOGLOBIN; IMATINIB; LONAFARNIB; TIPIFARNIB; BORONIC ACID DERIVATIVE; PIPERAZINE DERIVATIVE; PROTEASOME; PROTEINASE INHIBITOR; PYRAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ADULT; AGED; ANEMIA; ARTICLE; BASOPHIL; CANCER PATIENT; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL TRIAL; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; LEUKOCYTE COUNT; MALE; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA AND VOMITING; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PILOT STUDY; SIDE EFFECT; SURVIVAL TIME; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; APOPTOSIS; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; METABOLISM; MIDDLE AGED; MORTALITY;

AGED; APOPTOSIS; BASOPHILS; BORONIC ACIDS; DRUG RESISTANCE; FEMALE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PILOT PROJECTS; PIPERAZINES; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; PYRIMIDINES;

EID: 84555204856     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2011.06.004     Document Type: Article

References (43)

1. Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European Leukemia Net. J Clin Oncol 2009; 27:6041-51.
2. Deininger M, O'Brien SG, Guilhot F, et al. International Randomized Study of Interferon Vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Blood 2009; 114:Abstract 1126.
3. Apperley JF. Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol2007; 8:1018-29. (Pubitemid 47629897)
4. Hochhaus A, Baccarani M, Deininger M, et al. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia 2008; 22:1200-6. (Pubitemid 351833788)
5. Kantarjian HM, Giles F, Gattermann N, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 2007; 110:3540-6. (Pubitemid 350159618)
6. Apperley JF, Cortes JE, Kim DW, et al. Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial. J Clin Oncol2009; 27:3472-9.
7. Cortes J, Kim DW, Raffoux E, et al. Efficacy and safety of dasatinib in imatinib-resistant or-intolerant patients with chronic myeloid leukemia in blast phase. Leukemia 2008; 22:2176-83.
8. Giles FJ, Larson RA, Kantarjian HM, et al. Nilotinib in patients (pts) with Philadelphia chromosome-positive (ph +) chronic myelogenous leukemia in blast crisis (CML-BC) who are resistant or intolerant to imatinib. J Clin Oncol 2008; 26 (suppl):abstract 7017. Available at http://www.asco.org. Accessed June 17, 2011.
9. le Coutre P, Ottmann OG, Giles F, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or-intolerant accelerated-phase chronic myelogenous leukemia. Blood 2008; 111:1834-9. (Pubitemid 351451490)
10. Shah NP, Skaggs BJ, Branford S, et al. Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. JClin Invest 2007; 117:2562-9. (Pubitemid 47494357)
11. Copland M, Hamilton A, Elrick LJ, et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood 2006; 107:4532-9. (Pubitemid 43801382)
12. Graham SM, Jorgensen HG, Allan E, et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002; 99:319-25.
13. Jorgensen HG, Allan EK, Jordanides NE, et al. Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells. Blood 2007; 109:4016-9. (Pubitemid 46641755)
14. Bhatia R, Holtz M, Niu N, et al. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood 2003; 101:4701-7. (Pubitemid 36857723)
15. Rousselot P, Huguet F, Rea D, et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 2007; 109:58-60. (Pubitemid 46053043)
16. Cayrol C, Ducommun B. Interaction with cyclin-dependent kinases and PCNA modulates proteasome-dependent degradation of p21. Oncogene 1998; 17:2437-44. (Pubitemid 28544713)
17. Chadebech P, Brichese L, Baldin V, et al. Phosphorylation and proteasome-dependent degradation of Bcl-2 in mitotic-arrested cells after microtubule damage. Biochem Biophys Res Commun 1999; 262:823-7. (Pubitemid 29443742)
18. Clurman BE, Sheaff RJ, Thress K, et al. Turnover of cyclin E by the ubiquitin-proteasome pathway is regulated by cdk2 binding and cyclin phosphorylation. Genes Dev 1996; 10:1979-90. (Pubitemid 26346107)
19. Pagano M, Tam SW, Theodoras AM, et al. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 1995; 269:682-5.
20. Palombella VJ, Rando OJ, Goldberg AL, et al. The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell 1994; 78:773-85. (Pubitemid 24294453)
21. Reed SI. The ubiquitin-proteasome pathway in cell cycle control. Results Probl Cell Differ 2006; 42:147-81. (Pubitemid 44856951)
22. Magill L, Lynas J, Morris TC, et al. Proteasome proteolytic activity in hematopoietic cells from patients with chronic myeloid leukemia and multiple myeloma. Haematologica 2004; 89:1428-33. (Pubitemid 39643508)
23. Andreu EJ, Lledo E, Poch E, et al. BCR-ABL induces the expression of Skp2 through the PI3K pathway to promote p27Kip1 degradation and proliferation of chronic myelogenous leukemia cells. Cancer Res 2005; 65:3264-72. (Pubitemid 40524610)
24. Gesbert F, Sellers WR, Signoretti S, et al. BCR/ABL regulates expression of the cyclin-dependent kinase inhibitor p27Kip1 through the phosphatidylinositol 3-ki-nase/AKT pathway. JBiol Chem 2000; 275:39223-30. (Pubitemid 32058940)
25. Jonuleit T, van der Kuip H, Miething C, et al. Bcr-Abl kinase down-regulates cyclin-dependent kinase inhibitor p27 in human and murine cell lines. Blood 2000; 96:1933-9. (Pubitemid 30661080)
26. Dai Z, Quackenbush RC, Courtney KD, et al. Oncogenic Abl and Src tyrosine kinases elicit the ubiquitin-dependent degradation of target proteins through a Ras-independent pathway. Genes Dev 1998; 12:1415-24. (Pubitemid 28243627)
27. Hamdane M, David-Cordonnier MH, D'Halluin JC. Activation of p65 NF-kap-paB protein by p210BCR-ABL in a myeloid cell line (P210BCR-ABL activates p65 NF-kappaB). Oncogene 1997; 15:2267-75. (Pubitemid 27496978)
28. Reuther JY, Reuther GW, Cortez D, et al. A requirement for NF-kappaB activation in Bcr-Abl-mediated transformation. Genes Dev 1998; 12:968-81. (Pubitemid 28204604)
29. Dou QP, McGuire TF, Peng Y, et al. Proteasome inhibition leads to significant reduction of Bcr-Abl expression and subsequent induction of apoptosis in K562 human chronic myelogenous leukemia cells. J Pharmacol Exp Ther 1999; 289:781-90. (Pubitemid 29191232)
30. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348:2609-17. (Pubitemid 36741588)
31. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexa-methasone for relapsed multiple myeloma. N Engl J Med 2005; 352:2487-98. (Pubitemid 41007864)
32. San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008; 359:906-17.
33. Heaney NB, Pellicano F, Zhang B, et al. Bortezomib induces apoptosis in primitive chronic myeloid leukemia cells including LTC-IC and NOD/SCID repopulating cells. Blood 2010; 115:2241-50.
34. Thall PF, Sung HG. Some extensions and applications of a Bayesian strategy for monitoring multiple outcomes in clinical trials. Stat Med 1998; 17:1563-80. (Pubitemid 28367838)
35. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53:457-81.
36. Jabbour E, Kantarjian H, O'Brien S, et al. Predictive Factors for Response and Outcome in patients (pts) treated with second generation tyrosine kinase inhibitors (2-TKI) for chronic myeloid leukemia in chronic phase (CML-CP) post imatinib failure. [abstract] Blood 2009;114:Abstract 509.
37. Bringhen S, Larocca A, Rossi D, et al. Efficacy and safety of once weekly bortezomib in multiple myeloma patients. Blood 2010; 116:4745-53.
38. Argyriou AA, Iconomou G, Kalofonos HP. Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. Blood 2008; 112:1593-9.
39. Richardson PG, Briemberg H, Jagannath S, et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 2006; 24:3113-20. (Pubitemid 46638949)
40. Gatto S, Scappini B, Pham L, et al. The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in Bcr/Abl-positive cell lines sensitive and resistant to imatinib mesylate. Haematologica 2003; 88:853-63. (Pubitemid 37128085)
41. Albero MP, Vaquer JM, Andreu EJ, et al. Bortezomib decreases Rb phosphorylation and induces caspase-dependent apoptosis in imatinib-sensitive and-resistant Bcr-Abl1-expressing cells. Oncogene 2010; 29:3276-86.
42. Kuhn DJ, Chen Q, Voorhees PM, et al. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood 2007; 110:3281-90. (Pubitemid 350106321)
43. Jagannath S, Vij R, Stewart AK, et al. Initial results of PX-171-003, an open-label, single-arm, phase II study of carfilzomib (CFZ) in patients with relapsed and refractory multiple myeloma (MM). [abstract] Blood 2010; 116:abstract 864.